Taisho Pharmaceutical Holdings Co., Ltd.

TSE:4581 Rapport sur les actions

Capitalisation boursière : JP¥703.3b

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Taisho Pharmaceutical Holdings Résultats passés

Passé contrôle des critères 0/6

Taisho Pharmaceutical Holdings's earnings have been declining at an average annual rate of -25.1%, while the Pharmaceuticals industry saw earnings growing at 3.1% annually. Revenues have been growing at an average rate of 2.9% per year. Taisho Pharmaceutical Holdings's return on equity is 1.3%, and it has net margins of 2.6%.

Informations clés

-25.1%

Taux de croissance des bénéfices

-25.9%

Taux de croissance du BPA

Pharmaceuticals Croissance de l'industrie3.4%
Taux de croissance des recettes2.9%
Rendement des fonds propres1.3%
Marge nette2.6%
Dernière mise à jour des bénéfices31 Dec 2023

Mises à jour récentes des performances passées

Recent updates

Ventilation des recettes et des dépenses

Comment Taisho Pharmaceutical Holdings gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.

Historique des gains et des recettes

TSE:4581 Recettes, dépenses et bénéfices (JPY Millions )
DateRecettesLes revenusDépenses G+ADépenses de R&D
31 Dec 23320,3858,421143,52620,727
30 Sep 23319,96015,570138,81220,727
30 Jun 23313,11417,609136,76020,727
31 Mar 23301,38118,997134,10420,727
31 Dec 22295,82125,047131,88619,366
30 Sep 22282,56021,091131,63819,366
30 Jun 22273,38817,694133,20919,366
31 Mar 22268,20313,122133,72219,366
31 Dec 21267,7318,055135,03620,251
30 Sep 21266,2414,930134,70120,251
30 Jun 21270,8418,431134,99520,251
31 Mar 21281,98013,316135,77020,251
31 Dec 20291,48916,837135,08222,876
30 Sep 20302,21916,846140,06622,876
30 Jun 20303,29015,589140,90422,876
31 Mar 20288,52720,531136,04722,876
31 Dec 19272,99315,124132,21720,801
30 Sep 19264,26821,138123,10020,801
30 Jun 19260,06345,910118,74220,801
31 Mar 19261,55148,593118,15020,801
31 Dec 18264,19056,614115,41721,150
30 Sep 18270,95362,097118,78721,150
30 Jun 18273,30839,834119,88821,150
31 Mar 18280,09231,679124,85721,150
31 Dec 17279,14031,574125,33921,260
30 Sep 17277,39627,298125,70221,260
30 Jun 17278,87427,370127,05621,260
31 Mar 17279,77328,781125,00021,260
31 Dec 16281,58827,438124,30621,768
30 Sep 16285,15824,691124,66521,768
30 Jun 16290,35424,732124,24021,768
31 Mar 16290,13522,473126,16721,768
31 Dec 15293,71723,594126,16621,554
30 Sep 15294,67723,217127,42221,554
30 Jun 15291,33922,556148,8090
31 Mar 15290,49824,529124,72021,554
31 Dec 14289,77724,493126,87621,874
30 Sep 14293,19928,769124,44321,874
30 Jun 14296,15031,940122,24621,874
31 Mar 14295,95832,693121,13521,875
31 Dec 13292,83832,311117,99823,331
30 Sep 13289,77930,170118,79723,331
30 Jun 13285,57326,139118,37223,331

Des revenus de qualité: 4581 has a large one-off loss of ¥7.9B impacting its last 12 months of financial results to 31st December, 2023.

Augmentation de la marge bénéficiaire: 4581's current net profit margins (2.6%) are lower than last year (8.5%).

Analyse des flux de trésorerie disponibles par rapport aux bénéfices

Analyse de la croissance passée des bénéfices

Tendance des revenus: 4581's earnings have declined by 25.1% per year over the past 5 years.

Accélération de la croissance: 4581's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Bénéfices par rapport au secteur d'activité: 4581 had negative earnings growth (-66.4%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-4.1%).

Rendement des fonds propres

ROE élevé: 4581's Return on Equity (1.3%) is considered low.

Rendement des actifs

Rendement des capitaux employés

Découvrir des entreprises performantes dans le passé

7D

1Y

7D

1Y

7D

1Y